Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026

Vancouver and Boston based Xenon Pharmaceuticals Inc. (Nasdaq: XENE) revealed their plans to present various data at the 16th European Epilepsy Congress (EEC) in Athens, Greece from September 5-9, 2026. The company, focused on neuroscience, aims to develop and market transformative medications for patients. This event will showcase crucial insights for the medical community and patients alike.